Member Info for CityWatcher

Oriole might try and get more focus on their future operations and consolidate their shares soon - say 10 - 1 and that would equal 386m TVR. So investors would be happy to exit after a buy out approach, if it happens, whilst awaiting their gold pour. The price could well reach 50p, and that definitely with their prospects will get them noticed even more.

As I write this I see the share drop today has nearly disappeared. Excellent.

Having bought a few last Friday, I'm pleased it was only a few.

Stifel cuts Watches of Switzerland price target to 450 (690) pence - 'hold'

That's just for starters, it's the most recent forecast, more and most likely higher broker ratings to follow no doubt after their splendid results were posted.

19-Jan-24 Griffin Mining (GFM) Berenberg Bank Buy - 130.00 Reiteration

Have been pondering over Seribi, although I have enough of them & most are due a recovery in sp. I also have observed Oriole Resources is beginning to pick up and have posted about gold in Cameroon today and has been posting good news for their prospects regarding funding etc. Had an investment in the previous company 'Stratex' & still have. They were 7p so Oriole seems very cheap although 3.86bn shares are currently in issue. But good luck with any gold investment, there is also Griffin Mining.

I remember Solgold hovering around 4 1/2p and steadily rising up to 40p. So with their exciting prospects now it's definitely under priced with their prospects in Ecuador.

We need more gold diggers ( investors) in Solgold as it will deliver big time.

This was known about in the last year, but is now commencing.

Bulldozers have begun the mammoth task of demolishing 88 properties on a huge new housing development on the edge of the Cambridge today after developers discovered fatal defects - just after it had been built.

Barratt David Wilson Homes Cambridgeshire last year revealed last year that the homes, at the Darwin Green site in Cambridge, needed to be flattened after problems were identified with their foundations - at an eye-watering cost of £40million.

It explained: "To provide clarification, 36 homes currently at the roof stage of construction are scheduled for demolition and in addition to this, remediation will be undertaken on a further 47 plots, each at different stages of partial construction.

"Barratt and David Wilson Homes remains committed to ensuring that mitigation measures are in place to ensure that there is as little impact as possible to residents and the environment."

All airline stocks have suffered since the latest world news, even easyJet in spite of yesterday's big upgrade to their target price.

Bank of America raises easyJet to 'buy' (underperform) - price target 640 (470) pence

should be a good buy for recovery & they did have a write up in citya.m. that sounded promising.

have also included some market details.

market cap £11.98 million. shares in issue:217.88 million.

revenue reached £9.2m in december. back in june they bought the dirty martini chain.

near to 50 sites are owned across the uk. ****tails seem to be very popular.

the ex dragon's den star sarah willingham owns this company. '' we expect to see the benefits of the integration and the synergies during the coming year from the transformation of our management team and improving our systems.

Looking forward to their trading update next week too.

Broker Recommendations for Kier (KIE)

Date Broker Recommendation Old Target New Target Rating Type

09-Mar-23 Numis Buy 180.00 150.00 Reiteration

19-Jan-23 Numis Buy - - Reiteration

24-May-22 Peel Hunt Limited Buy - 200.00 Reiteration

24-Nov-21 Liberum Capital Buy 150.00 150.00 Reiteration

EasyJet

Airlines are often a hard sell for dealmakers. Pinning a valuation on a business that is so independent on oil prices - a cost largely outside management's control - is no mean feat. Nevertheless, speculation has swirled for some time that EasyJet is vulnerable to a takeover attempt, even though the company's share price rose by a third last year.

Despite this resurgence and its recent posting of record annual profits, the company looks cheap compared with competitors such as Ryanair. This - plus the fact that easyJet owns lots of valuable assets, such as its aircraft - puts the Luton- based carrier at number 3 on Quest's list of big-ticket takeover targets.

There is still a lot of excitement in this stock appletree1 & normally with such a low no. of shares in issue the price will move perhaps 18% - 30% in a day. It's a shame the company has not posted updates more often to interest their current investors, such as myself. Maybe if and when any rights issue is put forward we will find some surplus cash. So a great time perhaps to buy more of Genedrive to qualify for it.

So yes I do know a lot about GDR Roger65 & have been into and out of Genedrive stock since covid days, plus I also admire them for the babies hearing assistance test -

Genedrive plc (AIM:GDR), the point of care molecular diagnostics company, announces that the UK's National Institute for Health and Care Excellence (NICE) has preliminarily recommended that the Genedrive® MT-RNR1 ID Kit can be used by the NHS following the evidence review as part of their Early Value Assessment (EVA) Programme1.

But maybe for a fast return on your investment in the same field you should also have a chunk of money pushed into Futura Medical that is based in Guildford Surrey. Please enjoy their latest achievement. 'Boy' , us investors in their stock have been very patient, & are sure to reap big rewards soon. It might even be bought out as a bonus.

Good Luck, especially Roger65.

When Ascent consolidated their shares back in spring 2020, many shareholders of this stock thought they had been fleeced.

So any large holders owing to yesterday's news are most likely nearly hitting the sell button. So expect a further drop today as they decide to claw back what is available NOW.

These are the figures for Genedrive.

EPIC:GDRISIN:GB00B1VKB244Market cap:£9.95 million

Shares in issue:122.44 million

Sector:Pharmaceuticals & Biotechnology

So not many shares in issue causes the sp to rise a lot when investors get hungry for this stock.

Plus with GDR actively marketing in the Middle East . Surely the 'Skies the Limit'

Totally agree that with 3.86 billion shares in issue the spread can't be realistically what it's presently set to. Oriole is a penny share too, well defined as one.

Wow ! - Well done Ilovesushi , you were spot on. Amazingly your 'BOOM' comment was also the same day a rocket blasted off to the moon.

Reading the news today I reckon some selling has been done in error. For those investors who were unsuccessful with their last placing, owing to poor Royal Mail post probably, now is just as good a cause, if not better to invest in SCE. Could become a multi-bagger for patient investors. I liked some positivity in their news post.

So C4X Discovery Holdings plc received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca PLC, following trials of the C4X respiratory disease therapy treatment. The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November. In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.

This share is so undervalued now, so can't wait to top up on my holding ! There does not appear to be a better investment out there except maybe Futura Medical. Perhaps split any available monies between both of these.

Futura is eventually producing green shoots. Best to join the journey soon for the impressive rise. 4 bagger upwards when their results in 7 - 8 weeks are announced. Remember I told you so.

Placement of approximately $4.15 million of new ordinary shares of £0.01 each ("New Ordinary Shares") at a price of $0.255 per share ("Placement Price"), equivalent to 20.8p per share, to long term investors to increase the Company's cash resources, allowing it to pay December and March Convertible Bond payments in cash (the "Placement").

· David Hobbs, Pantheon's Executive Chairman, is contributing $250,000 of this sum.

It is expected that the New Ordinary Shares will be issued on or before 31 January 2024. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM at 8.00 a.m. on such date. It is expected that David Hobbs will also acquire $250,000 New Ordinary Shares at the Placement Price from IPGL on or before 31 January 2024.

Immediately following Admission, the Company's issued share capital will be 935,398,112 Ordinary Shares, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The total voting rights figure immediately following Admission, of 935,398,112